“The drug discovery process is growing in difficulty and length presenting challenges to leaders of drug discovery programs,” said Christina Burtsoff-Asp, GE Healthcare Life Sciences global product marketing manager for label-free technologies.
“With escalating cost pressures and increasingly complex disease targets, improving productivity in early drug discovery has been a challenge,” she told us.
In response, GE Healthcare Life Sciences has launched the Biacore 8K+, which, with up to 12 microplates, provides eight times higher throughput than a single-needle system, explained Burtsoff-Asp.
According to the company, the new system can automate more than 4,500 drug candidate/disease target binding experiments in a single run. Burtsoff-Asp said the system also can be paired with GE’s Biacore Insight Evaluation Software to evaluate screening and characterization data.
“The use of SPR as a bio-analytical tool has expanded in recent years to cover process optimization and quality control applications as well as early stage drug discovery,” said Burtsoff-Asp.
“SPR can support reliable analysis of critical quality attributes and is considered a novel analytical tool for drug product comparability testing.”